Advances in the treatment of Waldenström’s macroglobulinemia

References

• Dimopoulos MA, Panayiotidis P, Moulopoulos LA, Sfikakis P, Dalakas M. Waldenstrom’s macroglobulinemia: clinical features, complications, and management. J. Clin. Oncol. 18, 214–226 (2000).
   PubMed Web of Science ®Google Scholar
• Owen RG, Treon PP, Al-Katib A et al. Clinicopathological definition of Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenström’s Macroglobulinemia. Semin. Oncol. 30, 110–115 (2003).
   PubMed Web of Science ®Google Scholar
• Kyle RA, Treon SP, Alexanian R et al. Prognostic markers and criteria to initiate therapy in Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin. Oncol. 30, 116–120 (2003).
   PubMed Web of Science ®Google Scholar
• Facon T, Brouillard M, Duhamer A et al. Prognostic factors in Waldenström’s macroglobulinemia: a report of 167 cases. J. Clin. Oncol. 11, 1553–1558 (1993).
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Alexanian R. Waldenström’s macroglobulinaemia. Blood 83, 1452–1459 (1994).
   PubMed Web of Science ®Google Scholar
• Garcia-Sanz R, Montoto S, Torrequebrada A et al. Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases. Br. J. Haematol. 115, 575–582 (2001).
   PubMed Web of Science ®Google Scholar
• Kyle RA, Greipp PR, Gertz MA et al. Waldenström’s macroglobulinemia: a prospective study comparing daily with intermittent oral chlorambucil. Br. J. Haematol. 108, 7377–7342 (2000).
   Google Scholar
• Case DC, Ervin TJ, Boyd MA, Redfield DL. Waldenström’s macroglobulinemia: long term results with the M-2 protocol. Cancer Invest. 9, 1–7 (1991).
   PubMed Web of Science ®Google Scholar
• Annibali O, Petrucci MT, Martini V et al. Treatment of 72 newly diagnosed Waldenström macroglobulinemia cases with oral melphalan, cyclophosphamide, and prednisone. Cancer 103, 582–587 (2005).
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Jacobson JL, Gertz MA et al. Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (South West Oncology Group S9003). Blood 98, 41–48 (2001).
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Jacobson JL, Gertz MA, Crowley JJ, Barlogie B. Prognostic factors and response to fludarabine therapy in Waldenström’s macroglobulinemia: an update of a US Intergroup trial (SWOG S9003). Sem. Oncol. 30, 220–225 (2003).
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, O'Brien S, Kantarjian H et al. Fludarabine therapy in Waldenström’s macroglobulinemia. Am. J. Med. 95, 49–52 (1993).
   PubMed Web of Science ®Google Scholar
• Foran JM, Rohatiner AZ, Coiffier B et al. Multicentre Phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström’s macroglobulinaemia and mantle cell lymphoma. J. Clin. Oncol. 17, 546–553 (1999).
   PubMed Web of Science ®Google Scholar
• Thalhammer-Scherrer R, Geissler K, Schwarzinger I et al. Fludarabine therapy in Waldenström's macroglobulinemia. Ann. Hematol. 79, 556–559 (2000).
   PubMed Web of Science ®Google Scholar
• Maloisel F, Campos F, Giron C et al. Second treatment with fludarabine in a Waldenström’s macroglobulinemia patient. Leukemia 14, 220 (2000).
   Google Scholar
• Dimopoulos MA, Kantarjian H, Weber D et al. Primary therapy of Waldenström’s macroglobulinemia with 2-chlorodeoxyadenosine. J. Clin. Oncol. 12, 2694–2698 (1994).
   PubMed Web of Science ®Google Scholar
• Delannoy A, Van Den Neste E, Michaux JL, Bosly A, Ferrant A. Cladribine for Waldenström’s macroglobulinemia. Brit. J. Haematol. 104, 928–936 (1999).
   Google Scholar
• Liu ES, Burian C, Miller WE, Saven A. Bolus administration of cladribine in the treatment of Waldenström macroglobulinaemia. Br. J. Haematol. 103, 690–695 (1998).
   PubMed Web of Science ®Google Scholar
• Lewandowski K, Zaucha JM, Bieniaszewska M, Halaburda K, Hellmann A. 2-chlorodeoxyadenosine treatment of Waldenström’s macroglobulinemia – the analysis of own experience and the review of literature. Med. Sci. Monit. 6, 740–745 (2000).
   Google Scholar
• Weber DM, Dimopoulos MA, Delasalle K, Rankin K, Gavino M, Alexanian R. 2-chlorodeoxyadenosine alone and in combination for previously untreated Waldenström’s macroglobulinemia. Semin. Oncol. 30, 243–247 (2003).
   PubMed Web of Science ®Google Scholar
• Lewandowski K, Halaburda K, Hellman A. Fludarabine therapy in Waldenström’s macroglobulinaemia patients treated previously with 2-chlorodeoxyadenosine. Leuk. Lymphoma 43, 361–363 (2002).
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Weber D, Delasalle KB, Keating M, Alexanian R. Treatment of Waldenström’s macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: identification of prognostic factors. Ann. Oncol. 6, 49–52 (1995).
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Alexanian R, Koller CA, Kurzrock R, Keating MJ. Fludarabine therapy in macroglobulinemic lymphoma. Blood 75, 1928–1931 (1990).
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Gherlinzoni F, Bendandi M et al. Fludarabine treatment in resistant Waldenström’s macroglobulinemia. Eur. J. Haematol. 54, 120–123 (1995).
   PubMed Web of Science ®Google Scholar
• Leblond V, Ben-Othman T, Deconinck E et al. Activity of fludarabine in previously treated Waldenström’s macroglobulinemia: a report of 71 cases. J. Clin. Oncol. 16, 2060–2064 (1998).
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Kantarjian H, Estey E et al. Treatment of Waldenström macroglobulinemia with 2-chlorodeoxyadenosine. Ann. Intern. Med. 118, 195–198 (1993).
   PubMed Web of Science ®Google Scholar
• Leblond V, Levy V, Maloisel F et al. Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide–doxorubicin– prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease. Blood 98, 2640–2644 (2001).
   PubMed Web of Science ®Google Scholar
• Betticher DC, Hsu Schmitz SF, Ratschiller D et al. Cladribine (2-CDA) given as subcutaneous bolus injections is active in pre-treated Waldenström’s macroglobulinaemia. Br. J. Haematol. 99, 358–363 (1997).
   PubMedGoogle Scholar
• Dimopoulos MA, Hamilos G, Efstathiou E et al. Treatment of Waldenström’s macroglobulinemia with the combination of fludarabine and cyclophosphamide. Leuk. Lymphoma 44, 993–996 (2003).
   PubMed Web of Science ®Google Scholar
• Weber DM, Delasalle K, Gavino M, Alexanian R. 2-chlorodeoxyadenosine (2-CdA) and cyclophosphamide (Cy) alone or in combination with rituximab (Rit)for previously untreated Waldenström’s macroglobulinemia (WM). Blood 104, (2004) (Abstract 1476).
   Google Scholar
• Byrd JC, White CA, Link B et al. Rituximab therapy in Waldenström’s macroglobulinemia: preliminary evidence of clinical activity. Ann. Oncol. 10, 1525–1527 (1999).
   PubMed Web of Science ®Google Scholar
• Foran JM, Rohatiner AZ, Cunningham D et al. European Phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J. Clin. Oncol. 18, 317–324 (2000).
   PubMed Web of Science ®Google Scholar
• Treon SP, Agus TB, Link B et al. CD20-directed antibody-mediated Immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenström’s macroglobulinemia. J. Immunother. 24, 272–279 (2001).
   Web of Science ®Google Scholar
• Dimopoulos MA, Zomas A, Viniou NA et al. Treatment of Waldenström’s macroglobulinemia with Rituximab. J. Clin. Oncol. 20, 2327–2333 (2002).
   PubMed Web of Science ®Google Scholar
• Gertz MA, Rue M, Blood E, Kaminer LS, Vesole D, Greipp PR. Multicenter Phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group study (E3A98). Leuk. Lymphoma 45, 2047–2055 (2004).
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Zomas A, Viniou NA et al. Treatment of Waldenström’s macroglobulinemia with rituximab. J. Clin. Oncol. 20, 2327–2333 (2002).
   PubMed Web of Science ®Google Scholar
• Pestronk A, Florence J, Miller T, Choksi R, Al-Lozi MT, Levine TD. Treatment of IgM antibody associated polyneuropathies using rituximab. J. Neurol. Neurosurg. Psychiatry 74, 485–489 (2003).
   PubMed Web of Science ®Google Scholar
• Treon SP, Branagan AR, Hunter Z, Santos D, Tournhilac O, Anderson KC. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenström’s macroglobulinemia. Ann. Oncol. 15, 1481–1483 (2004).
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Fonseca R, Greipp PR et al. Initial immunoglobulin M ‘flare’ after rituximab therapy in patients diagnosed with Waldenström macroglobulinemia. Cancer 101, 2593–2598 (2004).
   PubMed Web of Science ®Google Scholar
• Krishna VM, Carey RW, Bloch KJ. Marked increase in serum IgM during treatment of Waldenström's macroglobulinemia with cladribine. N. Engl. J. Med. 348, 2045–2046 (2003).
   PubMed Web of Science ®Google Scholar
• Nicholos GL, Savage DG. Timing of rituximab/fludarabine in Waldenström’s macroglobulinemia may avert hyperviscosity. Blood 104, 2376 (2004) (Abstract 4612) .
   Google Scholar
• Owen RG, Rawstron AC, Osterborg A, Lundin J, Svensson G, Hillmen P. Activity of alemtuzumab in relapsed / refractory Waldenström’s macroglobulinemia. Blood 102, 644–645a (2003).
   Google Scholar
• Dimopoulos MA, Zomas A, Viniou NA et al. Treatment of Waldenström’s macroglobulinaemia with thalidomide. J. Clin. Oncol. 19, 3596–3601 (2001).
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Tsatalas C, Zomas A et al. Treatment of Waldenström's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone. Semin. Oncol. 30, 265–269 (2003).
   PubMed Web of Science ®Google Scholar
• Coleman M, Leonard J, Lyons L, Szelenyi H, Niesvizky R. Treatment of Waldenström's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone. Semin. Oncol. 30, 270–274 (2003).
   PubMed Web of Science ®Google Scholar
• Yang L, Wen B, Li H, Yang M, Jin Y, Yang S, Tao J. Autologous peripheral stem cell transplantation for Waldenström’s macroglobulinaemia. Bone Marrow Transplant. 24, 929–930 (1999).
   PubMed Web of Science ®Google Scholar
• Desikan R, Dhodapkar M, Siegel D et al. High dose therapy with autologous haemopoietic stem cell support for Waldenström’s macroglobulinemia. Br. J. Haematol. 105, 993–996 (1999).
   PubMed Web of Science ®Google Scholar
• Dreger P, Glass B, Kuse R et al. Myeloablative radiochemotherapy followed by reinfusion of purged autologous stem cells for Waldenström’s macroglobulinaemia. Br. J. Haematol. 106, 115–118 (1999).
   PubMed Web of Science ®Google Scholar
• Munshi NC, Barlogie B. Role for high-dose therapy with autologous hematopoietic stem cell support in Waldenstrom's macroglobulinemia. Semin. Oncol. 30, 282–285 (2003).
   PubMed Web of Science ®Google Scholar
• Anagnostopoulos A, Aleman A, Giralt S. Autologous and allogeneic stem cell transplantation in Waldenström's macroglobulinemia: review of the literature and future directions. Semin. Oncol. 30, 286–290 (2003).
   PubMed Web of Science ®Google Scholar
• Tournilhac O, Leblond V, Tabrizi R et al. Transplantation in Waldenström's macroglobulinemia – the French experience. Semin. Oncol. 30, 291–296 (2003).
   PubMed Web of Science ®Google Scholar
• Anagnostopoulos A, Dimopoulos MA, Aleman A et al. High-dose chemotherapy followed by stem cell transplantation in patients with resistant Waldenström’s macroglobulinemia. Bone Marrow Transplant. 27, 1027–1029 (2001).
   PubMed Web of Science ®Google Scholar
• Ueda T, Hatanaka K, Kosugi S, Kishino BI, Tamaki T. Successful non-myeloablative allogeneic peripheral blood stem cell transplantation (PBSCT) for Waldenström’s macroglobulinaemia with severe pancytopenia. Bone Marrow Transplant. 28, 609–611 (2001).
   PubMed Web of Science ®Google Scholar
• Tsai DE, Maillard I, Downs LH et al. Use of iodine 131I-tositumomab radioimmunotherapy in a patient with Waldenström's macroglobulinemia. Leuk. Lymphoma 45, 591–595 (2004).
   PubMed Web of Science ®Google Scholar
• Frankel SR. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenström's macroglobulinemia: a targeted approach to enhance apoptosis. Semin. Oncol. 30, 300–304 (2003).
   PubMed Web of Science ®Google Scholar
• Strauss SJ, Maharaj L, Stec J et al. Phase II clinical study of bortezomib (Velcade) in patients with relapsed/refractory non-Hodgkin’s lymphoma and Hodgkin’s disease. Blood 104, 389a (2004) (Abstract 1386).
   Google Scholar
• Johnson SA, Owen RG, Oscier DG et al. Phase III study of chlorambucil versus fludarabine as initial therapy for Waldenström’s macroglobulinaemia and related disorders. Clin. Lymphoma 5, 294–297 (2005).
   PubMedGoogle Scholar